Skip to main content
MMED logo

MiniMed Group, Inc. (MMED) Stock: Price, Forecast & Analyst Target

MiniMed Group, Inc. (MMED) — MoonshotScore 38/100 (Weak band), calculated Nov 18, 2026. Price $16.26 (-4.30%), as of the Nov 19, 2026 trading session; market cap $4.57B.

Educational signal · not a buy or sell recommendation · How to read this

$16.26 −$0.73 (-4.30%) Market Cap $4.57B

MiniMed Group, Inc. · MMED · NASDAQ · Healthcare · Medical - Equipment & Services

MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management.

Price as of Nov 19, 2026

Key Statistics

38 of 100

MoonshotScore v2 · MiniMed Group (MMED)

Weak
Business Quality Solid (70)
Financial Safety Sound (75)
Valuation Fair (63)
Growth Durability Flat (52)
Momentum Surging (81)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.

  • quarterly revenue $843M (Q1 FY2026, quarter ended Jul 2026)
  • EPS beat 0 of the last 3 reports
  • Altman Z 3.55 · Piotroski F 2

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MMED (57 recorded, newest six shown)
RecordedScoreBand
38Weak
38Weak
38Weak
38Weak
38Weak
38Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$16.26
Change on the day-4.30%
52-week range$10.65–$24.43
Market capitalisation$4.57B—
Shares traded on the day5.87M
Beta (volatility vs the S&P 500)-3.7

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Mar 6, 2026 to Nov 19, 2026: low $11, high $23, latest $16. $23 $11 high $23 Mar 6, 2026 Nov 19, 2026 · $16 $18Mar 6, 2026$17Mar 20, 2026$14Apr 2, 2026$14Apr 17, 2026$12May 1, 2026$11May 15, 2026$12May 29, 2026$15Jun 12, 2026$14Jun 26, 2026$15Jul 10, 2026$17Jul 24, 2026$20Aug 7, 2026$20Aug 21, 2026$23Sep 4, 2026$22Sep 18, 2026$20Oct 2, 2026$17Oct 16, 2026$18Oct 30, 2026$18Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for MiniMed Group (MMED): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Moderate
Valuation Moderate
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Strong
ROE Negative
Gross Margin Moderate

Read on: Nov 13, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 13, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is MiniMed Group (MMED), and what does it report?

Short answer

MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. MiniMed Group, Inc. (MMED) is listed on NASDAQ. Healthcare / Medical Equipment & Services SEC filing business address: Northridge, CA. It employs 8,000 people and is led by Que Thanh Dallara. In Q1 FY2026 it reported revenue of $843M and net income of $0. The market values it at $4.57B.

2 · Latest results

What do the latest results show for MiniMed Group (MMED)?

Short answer · as of

The most recent reported quarter, Q1 FY2026, carried revenue of $843M. Against analyst estimates the company has EPS beat 0 of the last 3 reports.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Apr 30, 2026Not availableNot availableNot availableNot available
Jan 31, 2026Not availableNot availableNot availableNot available
Oct 31, 2025Not availableNot availableNot availableNot available
Jul 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2026$843M$0—
Q4 FY2025$837M-$183M-$0.68 (diluted)
Q3 FY2025$790M-$119M-$0.42 (diluted)
Q2 FY2025$752M-$27M-$0.10 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for MiniMed Group (MMED)?

Short answer · as of

Cash and short-term investments were $0.00 at the Jul 31, 2026 balance-sheet date. This figure does not establish a cash runway. The MoonshotScore pillars rate business quality, balance-sheet strength, positive momentum as strengths. The distress and quality screens read Altman Z 3.55 · Piotroski F 2. Trailing ratios: ROE -9.1% · ROA -7.0% · current ratio 1.81 · earnings yield -6.3% · free-cash-flow yield -6.0%.

Data-derived red flags

  • Negative return on equity (-9.1%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at MiniMed Group (MMED)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $3.44B · EPS 0.69 · 11 analysts. Current published price targets run low $16.00 · high $30.00 · consensus $25.73 · median $28.00 against a quoted price of $16.26 (as of Nov 19, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does MiniMed Group compare with its peers?

Short answer

MiniMed Group's score ranks 3rd of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Envista Holdings Corp. (NVST) Same industry, near in market value$23.75 Nov 18, 2026$3.81B81 5-pillar Nov 18, 2026
Concentra Group Holdings Parent, Inc. (CON) Same industry, near in market value$41.98 Nov 18, 2026$5.28B78 5-pillar Nov 18, 2026
MiniMed Group (MMED) — this page$16.26$4.57B38
Park Dental Partners, Inc. (PARK) Same industry, near in market value$18.97 Nov 18, 2026$105M37 5-pillar Nov 18, 2026
Hims & Hers Health, Inc. (HIMS) Same industry, near in market value$17.05 Nov 18, 2026$4.00B31 5-pillar Nov 18, 2026
Beta Bionics, Inc. (BBNX) Same industry, near in market value$14.33 Nov 18, 2026$779M30 5-pillar Nov 18, 2026
CapsoVision, Inc. (CV) Same industry, near in market value$6.82 Nov 18, 2026$366M28 5-pillar Nov 18, 2026
Kindly MD, Inc. (NAKA) Same industry, near in market value$4.45 Nov 18, 2026$81.6M20 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$16.00 – $30.00
Consensus target
$25.73
Median target
$28.00
Revenue estimate
$3.44B
EPS estimate
$0.69

Consensus record · Captured .

Measured against a quoted price of $16.26 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 28, 2026

Transactions
34
Identified insiders
15
Purchases
0
Sales
0
Other transactions
34

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MMED in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MMED in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about MiniMed Group (MMED)?

Read these with our analysis →

What Investors Ask About MiniMed Group (MMED) — Healthcare

These answers are editorial: 1 of these 9 answers is drawn from the MMED research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for MMED?

MMED carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. MiniMed Group, Inc. specializes in medical technologies for diabetes management, including insulin pumps and continuous glucose monitoring systems.

Is MMED a good stock to buy?

Stock Expert AI does not rate MMED buy, sell or hold. MiniMed Group, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MMED stock price today?

The last price recorded for MiniMed Group, Inc. (MMED), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MMED price target?

The analyst consensus price target for MiniMed Group, Inc. (MMED), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does MiniMed Group, Inc. Common Stock do?

MiniMed Group, Inc. specializes in the design, production, and distribution of advanced medical technologies specifically for diabetes management. Its core offerings include a comprehensive suite of tools such as state-of-the-art insulin pumps, which facilitate precise insulin delivery, and continuous glucose monitoring (CGM) systems that provide real-time blood glucose data.

What are the key factors to evaluate for MMED?

MiniMed Group, Inc. (MMED) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Dividend Policy: No dividend yield, consistent with a growth-oriented company reinvesting earnings into R&D and market expansion. Not financial advice.

How frequently does MMED data refresh on this page?

MMED's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MMED's recent stock price performance?

MiniMed Group, Inc. (MMED) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive portfolio of diabetes management solutions, including insulin pumps and CGM systems. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MMED overvalued or undervalued right now?

MiniMed Group, Inc. (MMED) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 32 figures on this page — 1 from SEC filings and earnings calls, 23 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.